<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIM: Endoscopic surveillance for <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is costly, with one <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> detected every 48-441 patient years of follow up </plain></SENT>
<SENT sid="1" pm="."><plain>Genetic abnormalities, including loss of heterozygosity at sites of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes, have been detected in malignant and premalignant <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this prospective study was to determine if loss of heterozygosity analysis could identify patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> at greatest risk of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, for whom endoscopic surveillance is most appropriate </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Loss of heterozygosity analysis was performed on endoscopic biopsies from 48 patients as part of a Barrett's surveillance program using 14 microsatellite markers shown previously to detect loss of heterozygosity in more than 30% of esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were followed up endoscopically for a median of 5 years </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Loss of heterozygosity was detected in nine patients </plain></SENT>
<SENT sid="6" pm="."><plain>Three patients with loss of heterozygosity on chromosome 5q or 9p did not progress beyond <z:mpath ids='MPATH_160'>metaplasia</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Loss of heterozygosity at 17p11.1-p13 was detected in six patients, <z:hpo ids='HP_0000001'>all</z:hpo> of whom demonstrated <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and/or <z:mp ids='MP_0002038'>carcinoma</z:mp> during follow up (four low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, one high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and one <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Loss of heterozygosity at 17p11.1-p13 on chromosome 17p identifies patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> at risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> and can supplement histology in determining the frequency of endoscopy during surveillance </plain></SENT>
</text></document>